MiMedx Stock Soars 8.7% on Earnings, Analyst Revisions

MiMedx Group's stock surged 8.7% in pre-market trading on May 2, 2025, driven by a mix of analyst revisions and earnings reports.

Cantor Fitzgerald adjusted its price target for MiMedx, lowering it from $12 to $11 while maintaining an Overweight rating. This revision came after the company's earnings report, which showed earnings of $0.06 per share, matching estimates. Despite the earnings meeting expectations, the price target cut reflects concerns over potential delays in the launch of the company's LCD product.

Analysts have provided a range of price targets for MiMedx, with an average target of $13.50. However, the recent earnings call and discussions about LCD delays have led to a more cautious outlook. The company's stock has experienced volatility, with a 7% drop following the earnings report, highlighting investor sensitivity to product launch timelines and earnings performance.

Overall, while MiMedx's earnings met expectations, the market's reaction to the price target cuts and LCD delays indicates a need for the company to address these concerns to regain investor confidence.